Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, Pfizer Collaborate with Dako on Avelumab Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck, Pfizer Collaborate with Dako on Avelumab Alliance

Will work to develop companion diagnostic

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

As part of the global strategic alliance between Merck and Pfizer to develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have entered a collaboration with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).  Financial terms were not disclosed.
 
The agreement allows the three companies to work together to develop the CDx to assess programmed death-ligand 1 (PD-L1) protein expression levels in tumor tissue, and its microenvironment, including tumor-associated immune cells. The investigational CDx is part of the protocols in ongoing clinical trials of avelumab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics